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Study objectives: we performed an open-label
national study to evaluate the effects of Bosentan
on haemodynamics, exercise capacity, quality of
life, safety and tolerability in patients with chron-
ic thromboembolic pulmonary hypertension
(CTEPH).
Patients and methods: fifteen patients with
CTEPH not eligible or waiting for surgery were
enrolled. The primary endpoint was the change in
pulmonary vascular resistance (PVR). Secondary
endpoints included quality of life (measured by
the Minnesota living with heart failure question-
naire, MLHF), 6 minute walk distance (6MWD),
World Health Organization (WHO) functional
class, Borg dyspnoea scale, plasma endothelin,
serum values of disease severity such as uric acid,
N-terminal-pro brain natriuretic peptide (NT-
proBNP), C-reactive protein measured by a
highly sensitive method (CRPs) and other serum
and haemodynamic parameters.
Results: after six months of treatment with
bosentan, the PVR decreased from 852 (319) to
657(249) dyn*s*m-5 (p = 0.02). Quality of life
considerably improved from a mean total score of
48(14) to 35(17) (p = 0.003) with improvements in
the physical (from 25(5) to 17(7)) and emotional
(from 11(6) to 6(5)) subscores (p = 0.005 and
0.011), respectively. The 6MWD improved from
389(78) to 443(79) meters (p = 0.005). 4 patients
(27%) improved and 11 patients (73%) main-
tained their WHO class with no deterioration
during the six months of bosentan treatment (p =
0.02). Uric acid serum levels declined from
525(145) to 453(151) μmol/l (p = 0.006), NT-
proBNP and CRPs declined insignificantly.
 Endothelin serum levels increased from 4.3(1.5)
to 5.9(2.2) pg/ml (p = 0.025). Patients tolerated
the treatment well, and there were no severe ad-
verse events or deaths. 
Conclusion: this open-label study suggests a
beneficial effect of bosentan therapy not only on
pulmonary haemodynamics, but also on quality of
life and exercise capacity for patients with severe
CTEPH.  
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Chronic thromboembolic pulmonary hyper-
tension (CTEPH) is one of the most frequent
causes of pulmonary hypertension characterised
by intraluminal thrombus organisation, fibrous
stenosis and complete obliteration of pulmonary
arteries leading to right heart failure and impaired
survival [1, 2]. The true incidence of CTEPH
might be underestimated, as up to 4% of patients
with persistent dyspnoea after acute pulmonary
embolism develop CTEPH and many affected
patients do not have a history suggestive of
episodes of pulmonary embolism [3]. Although
surgical desobliteration of the pulmonary vascular
tree by pulmonary endarterectomy (PEA) is con-
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sidered the treatment of choice due to its curative
potential, only a subgroup of patients can benefit
from this procedure [4, 5]. Many patients with
CTEPH either suffer from a surgically inaccessi-
ble disease due to a distribution of the organised
embolic material mainly to the subsegmental and
smaller branches of the pulmonary vascular bed,
or suffer from severe medical co-morbidities pre-
cluding surgery [1, 2]. In addition, an unknown
number of operated patients may exhibit persist-
ent or recurrent pulmonary hypertension not
amenable to repeated surgery [2]. Furthermore,
the histopathological vascular changes of many
patients with CTEPH resemble those seen in
pulmonary arterial hypertension (PAH) including
endothelial proliferation and formation of plexi-
form lesions [6, 7], Moreover, CTEPH and PAH
may share acute vasoreactivity properties [8]. Left
untreated, the prognosis of CTEPH is poor 
with a reported 5-year mortality approaching
90% when the mean pulmonary artery pressure
(MPAP) is >30 mm Hg [9]. Taken together it
seems reasonable to postulate that patients with
CTEPH might benefit from medical therapy
with drugs that have been shown to be effective in
PAH. At present, there are no licensed medical
therapies for CTEPH. Case series and smaller
uncontrolled studies have reported improvements
in exercise capacity, markers of disease severity
and pulmonary haemodynamics with the use of
oral, inhaled or intravenous prostanoids, the
phosphodiesterase inhibitor sildenafil and re-
cently bosentan [10–19]. One randomised con-
trolled trial showing a favourable effect of inhaled
iloprost in pulmonary hypertension has included
patients with CTEPH, but subgroup analyses of
these subjects has not been reported [20].
Endothelin (ET)-1 plays a key role in pul-
monary arterial vessel remodelling as seen in pa-
tients with PAH and CTEPH [7]. Circulating en-
dothelin levels are elevated in correlation to dis-
ease severity and ET receptor subtypes (ETA and
ETB) are upregulated in PAH and possibly
CTEPH [21–24]. The dual endothelin receptor
antagonist bosentan has been shown to improve
exercise capacity and right ventricular function in
PAH [2, 17, 25], with sustained improvements and
survival shown in open label follow up studies up
to three years [26]. The aim of the present na-
tional open-label, non-controlled six month trial
was to characterise the effects of bosentan on pul-
monary haemodynamics, quality of life exercise
capacity, safety and tolerability in severely ill pa-
tients with CTEPH. 
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Patients and methods
Subject selection and inclusion criteria
Consecutive patients with CTEPH either not eligi-
ble for surgery or scheduled for PEA not earlier than 6
months and being orally anticoagulated for at least 6
months were included in this open-label, prospective
study conducted under the auspices of the Swiss Society
for Pulmonary Hypertension (SSPH) upon written in-
formed consent. The study was conducted in accordance
with the Declaration of Helsinki 1975 and was approved
by the ethical review boards of the involved and actively
recruiting centres. All patients had established pulmonary
hypertension confirmed by a mean pulmonary artery
pressure (mPAP) ≥25 mm Hg and a pulmonary artery oc-
clusion pressure ≤15 mm Hg at rest during right heart
catheterisation. Other inclusion criteria were severe limi-
tation in daily activity and exercise capacity assessed as
WHO functional class III-IV and a six minute walk dis-
tance (6MWD) between 150–500 meters, a pulmonary
vascular resistance (PVR) above 500 dyn*s*m-5 and a sta-
ble clinical condition including no changes in any poten-
tially vasoactive medication over the last three months
(eg, calcium channel blockers and angiotensin converting
enzyme inhibitors or other antihypertensive therapy,
prostanoids, sildenafil, longterm oxygen therapy). Exclu-
sion criteria were other forms of pulmonary hyperten-
sion, child-bearing potential without an acceptable
method of contraception and aspartate- and/or alanine
aminotransferases levels above three times the upper limit
of normal. The diagnosis of CTEPH was based on venti-
lation perfusion scanning and pulmonary angiography in
all patients. All patients were evaluated for PEA by an in-
terdisciplinary team consisting of pulmonologists, spe-
cialists in intensive care, radiologists and thoracic sur-
geons familiar with PEA. Included patients were either
not eligible for surgery due to distal disease, suffered from
significant comorbidities precluding surgery or were not
willing to undergo surgery within the next 6 months for
personal reasons. In these cases, the study was considered
as a bridging period prior to potential PEA.
Study assessments, treatment and outcomes
All patients were orally anticoagulated with phen-
procoumon (vitamin K antagonist, Marcoumar®) for at
least 6 months prior to study onset. After obtaining writ-
ten informed consent, all patients underwent a clinical as-
sessment including the determination of WHO func-
tional class by a standard questionnaire, completed the
Minnesota living with heart failure (MLHF) question-
naire for evaluation of quality of life [1, 27], performed
the 6MWD according to standard clinical practice with
assessment of blood pressure, heart rate and oxygen satu-
ration before and after the test, determination of the Borg
dyspnoea scale immediately after the 6MWD, pulmonary
function testing and right heart catheterisation for
haemodynamic measures. Additionally, peripheral blood
samples for complete haematogram, endothelin, C-reac-
tive protein assessed by a highly sensitive method (CRPs),
N-terminal pro-brain natriuretic peptide (here referred
to as pro-BNP), D-dimer, uric acid, bilirubin, liver func-
tion tests and arterial blood gas assessment were obtained.
For endothelin measurement, blood samples were imme-
diately centrifuged and the serum frozen at –20 °C. All
endothelin levels were then measured at once by enzyme-
linked immune assay according to the manufactures in-
structions. 
All patients meeting the inclusion criteria were then
started on bosentan (kindly provided by Actelion Pharma
Schweiz AG, Baden, Switzerland) 62.5 mg bid for the first
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4 weeks and then continued at the target dose of 125 mg
bid. Liver function tests were monitored every 2 weeks
over the first month and every 4 weeks thereafter accord-
ing to the treatment guidelines for bosentan. Patients
were evaluated on an outpatient basis at 4 week intervals
until the study end dated at 6 months. Every follow up
visit encompassed a clinical assessment with special at-
tention to potential adverse events, venous blood analysis
of liver enzymes and markers of disease severity (CRP,
pro-BNP, uric acid), determination of WHO functional
class, 6MWD and Borg dyspnoea scale. The study end
visit at 6 months additionally included a follow-up right
heart catheterisation with a full haemodynamic profile,
pulmonary function tests and assessment of quality of
life. Patients were followed 2 and 6 weeks after comple-
tion of the study for safety assessments. 
Since it was an open label study, the primary end-
point was chosen to be the change in PVR after 6 months
of bosentan treatment. Secondary endpoints were the
change in WHO functional class, 6MWD, Borg dysp-
noea scale, the MLHF scores (total score, physical- and
emotional-subscores), biochemical markers of disease
severity (CRP, pro-BNP, uric acid), changes in mPAP and
other haemodynamic values, changes in gas exchange and
pulmonary function testing.
Statistics
Patients’ characteristics at baseline and after treat-
ment are expressed as means and standard deviation (SD)
for continuous variables or number of subjects. Wilcoxon
signed rank test analysis was used to compare baseline
and end of study continuous variables. The Friedman test
was additionally applied where more than two consecu-
tive continuous variables were available (6MWD, bio-
chemical markers of disease severity). Patients with and
without vasodilatative combination therapy were com-
pared using the Mann-Whitney-U-Test. A p-value of
<0.05 was considered statistically significant. 
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Results
Patients
22 patients with CTEPH not eligible for sur-
gery within the next 6 months were screened for
the study. Five patients had to be excluded due to
a 6MWD >500 meters, 1 patient was excluded be-
cause of a PVR <500 dyn*s*m–5 and 1 patient was
Baseline After 6 months of Bosentan P-value
Age (yr) 67 (9)
Gender females/males 7 / 8
BMI (kg/m2) 24 (4) 24 (3) 0.70
WHO functional class II / III /IV 0 / 8 / 7 2 / 9 / 4 0.02
6MWD (m) 389 (78) 443 (79) 0.005*
MLHF total score 48 (14) 35 (17) 0.003*
MLHF physical subscore 25 (5) 17 (7) 0.005*
MLHF emotional subscore 11 (6) 6 (5) 0.011*
Haemodynamic parameters
Heart rate (beats/minute) 76 (10) 74 (16) 0.47
Mean systemic BP (mm Hg) 89 (15) 82 (11) 0.09
mPAP (mm Hg) 44 (8) 38 (7) 0.001*
Cardiac index (l/min/m2) 2.0 (0.5) 2.2 (0.5) 0.03*
PVR (dyn*sec*m–5) 852 (319) 657 (249) 0.02*
SVR (dyn*sec*m–5) 1897 (542) 1534 (349) 0.01*
RAP (mm Hg) 10 (4) 8 (5) 0.11
PAOP (mm Hg) 9 (3) 10 (4) 0.72
SaO2 (%) 89 (3) 89 (4) 0.35
SmvO2 (%) 54 (6) 55 (6) 0.18
Biochemical markers
Uric acid (mmol/l) 526 (145) 453 (151) 0.006*
Pro-BNP (ng/l) 3126 (2746) 2558 (2714) 0.158
CRPs (mg/l)# 10 (12) 8 (8) 0.11
Bilirubin (mg/l) 19 (3) 15 (2) 0.15
D-Dimer (mg/l)## 0.6 (0.7) 0.7 (0.6) 0.833
Troponin-T (normal <0.01 mg/l) 2 0
Data are presented as number of patients or mean values and standard deviation (SD). # = data of 3 patients missing. ## = data of 
5 patients missing. BMI: Body mass index , 6MWD: 6 minute walk distance, MLHF: Minnesota living with heart failure questionnaire
for Quality of Life assessment, BP: blood pressure, mPAP: Mean pulmonary arterial pressure, CI: Cardiac index, PVR: Pulmonary vas-
cular, resistance, RAP: Right atrial pressure, PAOP: Pulmonary artery occlusion pressure, Sa02: Arterial oxygen saturation,
Sv02: Mixed venous oxygen saturation, pro-BNP: NT-pro brain natriuretic peptide, CRPs: C-reactive protein assessed by a sensitive
method. *significant changes with p <0.05.
Table 1
Characteristics of 15
patients with Chronic
Thromboembolic Pul-
monary Hypertension
at baseline and after
6 months of Bosen-
tan therapy.
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already on bosentan therapy. Thus, a final number
of 15 patients were included in the study. The base-
line characteristics are presented in the table 1.
Subjects were severely ill and all of them were
 receiving chronic diuretics and long term oral an-
ticoagulation. Four patients (27%) were on con-
tinuous long term oxygen therapy. Six patients
(40%) were on stable therapy with inhaled ilo-
prost for more than 3 months (25(17) months),
none of the patients was taking sildenafil. Signifi-
cant comorbidities in a stable condition were arte-
rial hypertension (2 patients), mild chronic ob-
structive pulmonary disease (2), renal cell carci-
noma (1), and polycythaemia vera (1). Only 6 pa-
tients (40%) had a history of past acute pul-
monary embolism, and 2 patients (13%) recalled a
deep leg vein thrombosis. Except of the one with
carcinoma, none of the patients suffered from co-
agulopathy or thrombophilia. None of the pa-
tients had elevated liver enzymes at baseline. 
Haemodynamic response
Results of cardiac catheterization at baseline
and after 6 months of bosentan treatment are
shown in the table and in figure 1. The primary
endpoint, the PVR, significantly declined from
852(319) to 657(249) dyn*s*m-5 (p = 0.02). The
mPAP fell from 44(8) to 38(7) mm Hg (p = 0.001)
and cardiac index rose from 2.0(0.5) to 2.2(0.5)
l/min/m–2 (p = 0.03). The systemic vascular re-
sistance significantly decreased from 1897(542) to
1534(349) dyn*s*m–5 (p = 0.01). There were, how-
ever, no significant changes in mean blood pres-
sure, heart rate, right atrial and pulmonary artery
occlusion pressure, as well as arterial and mixed
venous blood saturation. The mean haemody-
namic changes over 6 months did not differ
 between the six patients on stable combination
therapy with inhaled Iloprost compared with the
other nine patients.
Functional assessments, exercise capacity 
and quality of life
At baseline, 8 patients were in WHO func-
tional class III and 7 patients in class IV. After 6
months of treatment, one patient each improved
from functional classes IV and III to class II and
two patients from class IV to class III. The re-
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Figure 1
PVR, mPAP and CI at
baseline and after six
months of Bosentan
treatment in 15 pa-
tients diagnosed with
CTEPH.
Figure 2
Six minute walk dis-
tance during different
time points of a six
month treatment pe-
riod with bosentan.
Data are presented as box plots, with the box representing the two middle quartiles (25–75%), the
bar in the box the median and the lengths of the whisker-lines represent the 1.5 fold interquartile
ranges. Outliers are represented separately as dots (adjacent numbers represent patient numbers).
The p-values are calculated by using the Wilcoxon test for two consecutive measurements. mPAP:
Mean pulmonary arterial pressure, CI: Cardiac index, PVR: Pulmonary vascular, resistance.
Data are presented as box plots, with the box representing
the two middle quartiles (25–75%), the bar in the box the
median and the lengths of the whisker-lines represent the
1.5 fold interquartile ranges. Outliers are represented sepa-
rately as dots (adjacent numbers represent patient num-
bers). The y-axis represents metres, the x-axis the different
time points as marked. The p-values are calculated by using
the Wilcoxon test for two consecutive measurements.
6MWD: 6 minute walk distance. 
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maining patients were assigned the same func-
tional class as at baseline. 
As shown in figure 2, the 6MWD signifi-
cantly increased from 389(78) to 443(79) meters
(p-Wilcoxon = 0.005, p-Friedman = 0.003),
whereas the Borg dyspnoea scale remained un-
changed (4.3(1.3) at baseline vs 4.6(1.7) at study
end, p = 0.8). Quality of life measured by the
MLHF questionnaire significantly improved
from a mean total score of 48(14) to 35(17) (p =
0.003) (figure 3). The physical as well as the emo-
tional subscore improved significantly from 25(5)
to 17(7) and from 11(6) to 6(5) (p = 0.005 and
0.011), respectively. There were no significant
changes in lung function parameters during the
study period.
Laboratory values
Uric acid serum levels were elevated above
the normal limit of 350 μmol/l in all patients at
baseline with a mean level of 525(145). They de-
creased to 453(151) μmol/l (p = 0.006) during the
study and normalised in 6 patients (40%). The
endothelin-1 serum level could be measured in 8
patients (53%). The mean endothelin-1 serum
level increased from 4.26(1.5) to 5.86(2.2) pg/ml
(p = 0.025) during the six month of bosentan
treatment. Serum levels of pro-BNP were ele-
vated above the upper normal limit (334 ng/l) in
13 (87%) patients at baseline and study end. Mean
pro-BNP serum levels insignificantly decreased
from 3126(2746) to 2558(2714) ng/l (p = 0.16)
during the study. Serum levels of CRPs at baseline
were missing in 3 patients. Of the remaining 12,
none had a normal level (<1 mg/l). Ten showed
moderately (1–10 mg/ml) and 2 highly (>10 mg/l)
elevated serum levels of CRPs. The mean levels
slightly decreased during the study from 9.65(12)
to 7.73(9) mg/l (p = 0.11), respectively, with one
patient with normal, 8 with moderate and 3 with
high CRP-levels at study end. Bilirubin serum
levels were elevated above the normal limit of 17
μg/l in 7 patients (47%) at baseline and 5 patients
(33%) at study end, the mean levels did not de-
crease significantly during the study (19(3) vs
15(2) μg/l, p = 0.15). D-Dimers measures were
missing in five patients at baseline. Of the remain-
ing 10 patients, two had levels above the labora-
tory norm of 0.5 mg/l at baseline and four at
study end. The mean levels insignificantly in-
creased from 0.6(0.7) to 0.7(0.6) mg/l (p = 0.833).
Serum levels of troponin T were slightly above
the detection limit of 0.01 μg/l in two patients at
baseline (0.02 and 0.04 μg/l), and were unde-
tectable in all patients at study end. 
Side effects and adverse events
The liver enzymes alanine and aspartate
aminotransferases were within normal limits at
baseline and remained there during the 6 months
study period in all patients. Systemic blood pres-
sure, heart rate, body weight and haemoglobin
did not change significantly during the study and
no patient experienced episodes of right heart
failure or symptomatic hypotension during the
study period. The study medication was tolerated
very well. The most frequent side effect was slight
ankle oedema in 5 patients and one patient devel-
oped mild ascites during the 5th month of treat-
ment. Minor adverse events during the study
were respiratory tract infections in two patients.
There were no serious adverse events during the
whole 6 months study period. The patient in-
cluded with previously stable renal cell carcinoma
developed rapid tumour progression and died
within three months of study end. Another pa-
tient died three weeks after completing the study
after unsuccessful cardiopulmonary resuscitation
due to ventricular tachycardia. The patient was on
continued bosentan therapy, and his death was
judged not to be correlated with the study drug
but due to CTEPH itself.
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Figure 3
Quality of life meas-
ured by the Min-
nesota living with
heart failure ques-
tionnaire at baseline,
three and six month
of Bosentan treat-
ment.
Data are presented as box plots, with the box representing
the two middle quartiles (25–75%), the bar in the box the
median and the lengths of the whisker-lines represent the
1.5 fold interquartile ranges. Outliers are represented sepa-
rately as dots (adjacent numbers represent patient num-
bers). The y-axis represent test points (higher numbers rep-
resent worse quality of life), the x-axis the different time
points as marked. The p-values are calculated using the
Wilcoxon test for consecutive measurements. 
Discussion
Our study confirms the favorable effect of
bosentan therapy to improve pulmonary haemo-
dynamics and exercise capacity in CTEPH not el-
igible for PEA. In addition, a positive effect on
quality of life could be demonstrated. Although
PEA is the only curative therapy for patients with
CTEPH, many patients do not qualify for this
surgical option due to distal pulmonary vascular
573-580 Ulrich 11819-07.qxp  11.10.2007  13:41 Uhr  Seite 577
disease, contraindications or significant comor-
bidity [4, 8]. Currently, no specific randomised
trial-based therapeutic recommendations exist for
these patients. Although the pathogenesis of
CTEPH still remains incompletely understood, it
is becoming increasingly clear that beside a possi-
bly initiating thromboembolic obstruction of pul-
monary vessels, vascular remodeling plays a im-
portant role in CTEPH as well [7, 28]. The mor-
phological changes of the vessel wall resemble
those found in PAH and may also lead to en-
dothelial dysfunction. Thus, the use of vasoactive
treatment in chronic thromboembolic disease in
analogy to PAH seems reasonable. Several phar-
macological strategies have been employed in pa-
tients with CTEPH not eligible for PEA or as a
bridge to surgery. Smaller studies demonstrated a
favourable effect of prostanoids and sildenafil on
pulmonary haemodynamics and/or exercise ca-
pacity in these patients [10, 12, 15, 20]. Another
therapeutic option in patients with PAH is en-
dothelin antagonism [23]. As plasma levels of big-
endothelin-1, the precursor of endothelin-1, are
increased in patients with CTEPH compared to
control subjects and upregulation of endothelin B
receptors have been demonstrated in pulmonary
arterial smooth muscle cells of patients with this
disease [29], a treatment with an endothelin re-
ceptor antagonist in patients with CTEPH seems
reasonable. The increased endothelin levels may
also suggest that CTEPH and PAH share patho-
genic pathways. Therefore, endothelin antago-
nism may be important in the treatment of
CTEPH as well, as supported by the present
study. Indeed, recently a beneficial effect of
bosentan therapy on exercise capacity and func-
tional class in CTEPH was demonstrated in three
small prospective trials [16, 17, 19], one of which
also demonstrated an amelioration of pulmonary
haemodynamics [17]. Additionally, a sustained
favourable effect of bosentan in inoperable
CTEPH was demonstrated by a retrospective
chart review of 47 patients after one year [18]. 
Our study confirms these favourable results
of bosentan therapy in CTEPH not eligible for
PEA. Pulmonary haemodynamics significantly
improved after 6 months of treatment with sig-
nificant decreases in PVR, the primary endpoint.
There was a significant mean increase in the
6MWD of 58 m, and thus comparable to the
study of Hoeper and Hughes and colleagues [17,
18]. The mean Borg dyspnoea scale immediately
after the test remained unchanged. This may be
attributed to a similar effort for the increased dis-
tance walked at study end compared with base-
line. 
Beside the improvements in haemodynamics
and exercise capacity, this study is the first to show
a significant improvement in quality of life in
CTEPH under bosentan therapy. Nowadays,
quality of health parameters are becoming in-
creasingly relevant, especially in serious disorders
requiring difficult and costly treatments. Re-
cently, we were even able to demonstrate that
quality of life belongs to the most important pre-
dictors of disease progression, with the MLHF
total score is the sole factor predicting subsequent
outcome in a multivariate analysis [26]. Although
its measurement is subjective, amelioration of
quality of life is the parameter considered most
important for the patients’ well being and corre-
lates with prognosis. Moreover, it is one of the
most important factors for patients and decision
making in health authorities [30, 31]. 
Hyperuricaemia has been shown to be associ-
ated with elevated right and left heart filling pres-
sures and correlates with disease severity and
mortality in patients with pulmonary arterial hy-
pertension [32–35] and uric acid serum levels
were shown to decrease in about two third of pa-
tients under intravenous prostanoid therapy [35].
In the present study, we found elevated baseline
uric acid serum levels in all patients, with a signifi-
cant decrease in mean uric acid serum levels, and
a normalisation of the values in 6 patients (40%)
at study end. It can be speculated, that in analogy
to PAH, these findings might be associated with a
improved prognosis [32]. Another important
marker of disease severity in right and left heart
failure is pro-BNP [36]. In our cohort, pro-BNP
serum levels were elevated at baseline in all but
one patient, and decreased during the treatment
period. As experimental data suggest that block-
age of ET could directly reduce BNP levels inde-
pendently of the haemodynamic effect, the inter-
pretation of this marker seems to be difficult [37].
However, in contrast to other published observa-
tional studies, the mean serum level decrease dur-
ing this study did not reach statistical significance.
A high level of CRPs is a marker of endothelial
dysfunction in the systemic circulation [38, 39].
We found high to very high levels of CRPs levels
in 11 of the 12 tested patients (92%) at baseline.
During the study, CRPs levels decreased in 7 pa-
tients (58%), however, the change of overall mean
levels not being significant. The considerably
high baseline CRPs levels in this small CTEPH-
cohort are remarkable and reinforce the implica-
tion of inflammatory mechanisms in the patho-
genesis of CTEPH. Elevation of proinflamma-
tory mediators have also been reported in patients
with idiopathic pulmonary arterial hypertension
and CTEPH [40–44]. Whether CRPs is a marker
of endothelial dysfunction in the pulmonary cir-
culation analogous to the systemic circulation has
only been studied in a limited fashion to date [45].
The findings of this small cohort support the pos-
sible value of CRPs as a marker of disease severity
in CTEPH. 
Six of the fifteen study patients were on stable
therapy with inhaled Iloprost. The mean changes
in all assessed parameters were not different in
this subgroup compared with the remainder. This
may indicate that even patients on stable vasodila-
tor therapy with another drug could further profit
by adding Bosentan therapy. However, the
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presently investigated cohort was not intended to
answer the question about vasodilator combina-
tion therapy in CTEPH. Therefore, further
larger clinical studies are warranted to enlighten
this question. 
Bosentan therapy was very well tolerated in
this study population. None of the patient had
quit therapy or decreased the target dose due to
side effects or elevated liver enzymes. Reported
side effects were minor leg oedema and ascites in
one patient. These data are in concordance with
previous studies of bosentan in patients with PAH
and CTEPH, showing that doses up to 250 mg
twice daily can be safely administered under strict
monitoring [16–18, 23]. 
The limitation of the present study is the lack
of a control population and it’s limited sample
size. Thus, it can not be excluded that the ob-
served improvements in functional class, exercise
capacity and quality of life were due to a placebo
effect. However, the significant improvements in
the objective primary study end point, namely the
PVR, as well as uric acid serum levels reflecting
another important parameter of disease severity,
can hardly be attributed to a placebo effect only
and underscore the efficacy of bosentan in a co-
hort of CTEPH with proximal and distal involve-
ment.
In conclusion, the results of this study suggest
that therapy with the dual Endothelin receptor
antagonist bosentan is well tolerated and can re-
sult in a sustained improvement in pulmonary
haemodynamics, quality of life, WHO functional
class, exercise capacity and markers of disease
severity in a broad collective of CTEPH not suit-
able for PEA for various reasons or as a bridge to
PEA in some patients. Nevertheless, all patients
with CTEPH should first be evaluated for the po-
tentially curative PEA procedure and receive anti-
coagulation therapy. 
Correspondence:
Dr. med. Silvia Ulrich
Department of Internal Medicine
Rämistrasse 100
CH-8005 Zurich
Switzerland
E-Mail: silvia.ulrich@usz.ch
S W I S S  M E D  W K LY 2 0 0 7 ; 13 7 : 5 7 3 – 5 8 0  ·  w w w. s m w. ch
References
1 Dartevelle P, Fadel E, Mussot S, et al. Chronic thromboem-
bolic pulmonary hypertension. Eur Respir J. 2004;23:637–48.
2 Hoeper MM, Mayer E, Simonneau G, Rubin LJ. Chronic
thromboembolic pulmonary hypertension. Circulation. 2006;
113:2011–20.
3 Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic
thromboembolic pulmonary hypertension after pulmonary
embolism. N Engl J Med. 2004;350:2257–64.
4 Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic throm-
boembolic pulmonary hypertension. N Engl J Med. 2001;345:
1465–72.
5 Klepetko W, Mayer E, Sandoval J, et al. Interventional and sur-
gical modalities of treatment for pulmonary arterial hyperten-
sion. J Am Coll Cardiol. 2004;43:73S–80S.
6 Moser KM, Fedullo PF, Finkbeiner WE, Golden J. Do patients
with primary pulmonary hypertension develop extensive cen-
tral thrombi? Circulation. 1995;91:741–5.
7 Humbert M, Morrell NW, Archer SL, et al. Cellular and mo-
lecular pathobiology of pulmonary arterial hypertension. J Am
Coll Cardiol. 2004;43:13S–24S.
8 Ulrich S, Fischler M, Speich R, Popov V, Maggiorini M.
Chronic thromboembolic and pulmonary arterial hypertension
share acute vasoreactivity properties. Chest. 2006;130:
841–6.
9 Riedel M, Stanek V, Widimsky J, Prerovsky I. Longterm fol-
low-up of patients with pulmonary thromboembolism. Late
prognosis and evolution of hemodynamic and respiratory data.
Chest. 1982;81:151–8.
10 Bresser P, Fedullo PF, Auger WR, et al. Continuous intra-
venous epoprostenol for chronic thromboembolic pulmonary
hypertension. Eur Respir J. 2004;23:595–600.
11 Scelsi L, Ghio S, Campana C, et al. Epoprostenol in chronic
thromboembolic pulmonary hypertension with distal lesions.
Ital Heart J. 2004;5:618–23.
12 Nagaya N, Sasaki N, Ando M, et al. Prostacyclin therapy before
pulmonary thromboendarterectomy in patients with chronic
thromboembolic pulmonary hypertension. Chest. 2003;123:
338–43.
13 Ono F, Nagaya N, Okumura H, et al. Effect of orally active
prostacyclin analogue on survival in patients with chronic
thromboembolic pulmonary hypertension without major vessel
obstruction. Chest. 2003;123:1583–8.
14 Roig Figueroa V, Herrero Perez A, de la Torre Ferrera N, Her-
nandez Garcia E, Aller Alvarez JL, Para Cabello J. Iloprost for
chronic thromboembolic pulmonary hypertension. Arch Bron-
coneumol. 2004;40:326–8.
15 Ghofrani HA, Schermuly RT, Rose F, et al. Sildenafil for long-
term treatment of nonoperable chronic thromboembolic pul-
monary hypertension. Am J Respir Crit Care Med. 2003;167:
1139–41.
16 Bonderman D, Nowotny R, Skoro-Sajer N, et al. Bosentan
therapy for inoperable chronic thromboembolic pulmonary
hypertension. Chest. 2005;128:2599–603.
17 Hoeper MM, Kramm T, Wilkens H, et al. Bosentan therapy for
inoperable chronic thromboembolic pulmonary hypertension.
Chest. 2005;128:2363–7.
18 Hughes RJ, Jais X, Bonderman D, et al. The efficacy of bosen-
tan in inoperable chronic thromboembolic pulmonary hyper-
tension: a 1-year follow-up study. Eur Respir J. 2006;28:138–
43.
19 Seyfarth HJ, Hammerschmidt S, Pankau H, Winkler J, Wirtz
H. Long-Term Bosentan in Chronic Thromboembolic Pul-
monary Hypertension. Respiration 2006.
20 Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost
for severe pulmonary hypertension. N Engl J Med. 2002;347:
322–9.
21 Allen SW, Chatfield BA, Koppenhafer SA, Schaffer MS, Wolfe
RR, Abman SH. Circulating immunoreactive endothelin-1 in
children with pulmonary hypertension. Association with acute
hypoxic pulmonary vasoreactivity. Am Rev Respir Dis. 1993;
148:519–22.
22 Rubens C, Ewert R, Halank M, et al. Big endothelin-1 and en-
dothelin-1 plasma levels are correlated with the severity of pri-
mary pulmonary hypertension. Chest. 2001;120:1562–9.
23 Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for
pulmonary arterial hypertension. N Engl J Med. 2002;346:
896–903.
24 Kim DK, Lim SW, Lee S, et al. Serotonin transporter gene
polymorphism and antidepressant response. Neuroreport.
2000;11:215–9.
25 Galie N, Hinderliter AL, Torbicki A, et al. Effects of the oral
endothelin-receptor antagonist bosentan on echocardiographic
and doppler measures in patients with pulmonary arterial hy-
pertension. J Am Coll Cardiol. 2003;41:1380–6.
573-580 Ulrich 11819-07.qxp  11.10.2007  13:42 Uhr  Seite 579
26 Cenedese E, Speich R, Dorschner L, et al. Measurement of
quality of life in pulmonary hypertension and its significance.
Eur Respir J 2006.
27 Jamieson SW, Kapelanski DP, Sakakibara N, et al. Pulmonary
endarterectomy: experience and lessons learned in 1,500 cases.
Ann Thorac Surg. 2003;76:1457–62; discussion 1462–4.
28 Chaouat A, Weitzenblum E and Higenbottam T. The role of
thrombosis in severe pulmonary hypertension. Eur Respir J.
1996;9:356–63.
29 Bauer M, Wilkens H, Langer F, Schneider SO, Lausberg H,
Schafers HJ. Selective upregulation of endothelin B receptor
gene expression in severe pulmonary hypertension. Circula-
tion. 2002;105:1034–6.
30 Idler EL, Benyamini Y. Self-rated health and mortality: a re-
view of twenty-seven community studies. J Health Soc Behav.
1997;38:21–37.
31 Idler EL, Russell LB, Davis D. Survival, functional limitations,
and self-rated health in the NHANES I Epidemiologic Fol-
low-up Study, 1992. First National Health and Nutrition Ex-
amination Survey. Am J Epidemiol. 2000;152:874–83.
32 Bendayan D, Shitrit D, Ygla M, Huerta M, Fink G, Kramer
MR. Hyperuricemia as a prognostic factor in pulmonary arte-
rial hypertension. Respir Med. 2003;97:130–3.
33 Hoeper MM, Hohlfeld JM, Fabel H. Hyperuricaemia in pa-
tients with right or left heart failure. Eur Respir J. 1999;13:
682–5.
34 Nagaya N, Uematsu M, Satoh T, et al. Serum uric acid levels
correlate with the severity and the mortality of primary pul-
monary hypertension. Am J Respir Crit Care Med. 1999;160:
487–92.
35 Voelkel MA, Wynne KM, Badesch DB, Groves BM, Voelkel
NF. Hyperuricemia in severe pulmonary hypertension. Chest.
2000;117:19–24.
36 Kragelund C, Omland T. B-type natriuretic peptide (BNP) or
N-terminal-proBNP for the diagnosis of heart failure: which
peptide is the better choice? Scand J Clin Lab Invest. 2005;
65:629–32.
37 Magga J, Vuolteenaho O, Marttila M, Ruskoaho H. Endothe-
lin-1 is involved in stretch-induced early activation of B-type
natriuretic peptide gene expression in atrial but not in ventric-
ular myocytes: acute effects of mixed ET(A)/ET(B) and AT1
receptor antagonists in vivo and in vitro. Circulation. 1997;
96:3053–62.
38 Fichtlscherer S, Breuer S, Schachinger V, Dimmeler S, Zeiher
AM. C-reactive protein levels determine systemic nitric oxide
bioavailability in patients with coronary artery disease. Eur
Heart J. 2004;25:1412–8.
39 Fichtlscherer S, Zeiher AM. Endothelial dysfunction in acute
coronary syndromes: association with elevated C-reactive pro-
tein levels. Ann Med. 2000;32:515–8.
40 Voelkel NF, Cool C, Lee SD, Wright L, Geraci MW, Tuder
RM. Primary pulmonary hypertension between inflammation
and cancer. Chest. 1998;114:225S–230S.
41 Dorfmuller P, Zarka V, Durand-Gasselin I, et al. Chemokine
RANTES in severe pulmonary arterial hypertension. Am J
Respir Crit Care Med. 2002;165:534–9.
42 Fartoukh M, Emilie D, Le Gall C, Monti G, Simonneau G,
Humbert M. Chemokine macrophage inflammatory protein-
1alpha mRNA expression in lung biopsy specimens of primary
pulmonary hypertension. Chest. 1998;114:50S–51S.
43 Nicolls MR, Taraseviciene-Stewart L, Rai PR, Badesch DB,
Voelkel NF. Autoimmunity and pulmonary hypertension: a
perspective. Eur Respir J. 2005;26:1110–8.
44 Bondermann DG-S E, Jakowitsch J, Exner M, Zechner R,
Rezaie-Majd S, Lang MB, et al. Infection is a Mechanism Un-
derlying Thrombus Persistence in Chronic Thromboembolic
Pulmonary Hypertension (CTEPH). Cardiology. 2002;9:16–7.
45 Joppa P, Petrasova D, Stancak B, Tkacova R. Systemic inflam-
mation in patients with COPD and pulmonary hypertension.
Chest. 2006;130:326–33.
580Bosentan therapy for chronic thromboembolic pulmonary hypertension
573-580 Ulrich 11819-07.qxp  11.10.2007  13:42 Uhr  Seite 580
What Swiss Medical Weekly has to offer:
• SMW’s impact factor has been steadily 
rising. The 2005 impact factor is 1.226.
• Open access to the publication via
the Internet, therefore wide audience 
and impact
• Rapid listing in Medline
• LinkOut-button from PubMed 
with link to the full text 
website http://www.smw.ch (direct link
from each SMW record in PubMed)
• No-nonsense submission – you submit 
a single copy of your manuscript by 
e-mail attachment 
• Peer review based on a broad spectrum 
of international academic referees
• Assistance of our professional statistician
for every article with statistical analyses
• Fast peer review, by e-mail exchange with
the referees 
• Prompt decisions based on weekly confer-
ences of the Editorial Board
• Prompt notification on the status of your
manuscript by e-mail
• Professional English copy editing
• No page charges and attractive colour 
offprints at no extra cost
Editorial Board
Prof. Jean-Michel Dayer, Geneva
Prof. Peter Gehr, Berne
Prof. André P. Perruchoud, Basel
Prof. Andreas Schaffner, Zurich 
(Editor in chief)
Prof. Werner Straub, Berne
Prof. Ludwig von Segesser, Lausanne
International Advisory Committee
Prof. K. E. Juhani Airaksinen, Turku, Finland
Prof. Anthony Bayes de Luna, Barcelona, Spain
Prof. Hubert E. Blum, Freiburg, Germany
Prof. Walter E. Haefeli, Heidelberg, Germany
Prof. Nino Kuenzli, Los Angeles, USA
Prof. René Lutter, Amsterdam, 
The Netherlands
Prof. Claude Martin, Marseille, France
Prof. Josef Patsch, Innsbruck, Austria
Prof. Luigi Tavazzi, Pavia, Italy
We evaluate manuscripts of broad clinical
interest from all specialities, including experi-
mental medicine and clinical investigation.
We look forward to receiving your paper!
Guidelines for authors:
http://www.smw.ch/set_authors.html
All manuscripts should be sent in electronic form, to:
EMH Swiss Medical Publishers Ltd.
SMW Editorial Secretariat
Farnsburgerstrasse 8
CH-4132 Muttenz
Manuscripts: submission@smw.ch
Letters to the editor: letters@smw.ch
Editorial Board: red@smw.ch
Internet: http://www.smw.ch
The many reasons why you should 
choose SMW to publish your research 
Editores Medicorum Helveticorum
S w i s s  M e d i c a l  W e e k l y
E s t a b l i s h e d  i n  1 8 7 1
F o r m e r l y :  S c h w e i ze r i s c h e  M e d i z i n i s c h e  W o c h e n s c h r i f t
O f f i c i a l  j o u r n a l  o f t h e  S w i s s  S o c i e t y  o f  I n f e c t i o u s
d i s e a s e s ,  t h e  S w i s s  S o c i e t y  o f  I n t e r n a l  M e d i c i n e
a n d  t h e  S w i s s  R e s p i r a t o r y  S o c i e t y
